Drug Description in Trials / DrugBank / KEGG DRUG /

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1(-)-Epicatechin1件: Epicatechin---2件: 86, 113
2(Pyr1)apelin-13----1件: 86
3(S)-2-(4,6-dimethylpyrimidin-2-yloxy)-3-methoxy-3,3-diphenylpropanoic acid----1件: 86
4(S)-3-((3-(1-((6-(3,4-DIMETHOXYPHENYL)PRYAZIN-2- YL)AMINO)ETHYL)PHENYL)CARBAMOYL)-5-METHYLPRIDIN-1-IUM----1件: 86
5(S)-3-((3-(1-((6-(3,4-DIMETHOXYPHENYL)PRYAZIN-2-YL)AMINO)ETHYL)PHENYL)CARBAMOYL)-5-METHYLPRIDIN-1-IUM----1件: 86
6**Comment**- IMP inhalation solution identical to ventavis inhalation solution, but IMP is in a different volume presentation. Please see covering letter.1件: Iloprost1件: D02721 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
710-nitro-9(E)-octadec-9-enoic acid----1件: 86
811C-ACETATE2件: Acetate,
Acetic acid C-11		---3件: 13, 86, 88
9120 mg sodium nitrite inhalation solution1件: Nitrite---1件: 86
10129Xe Hyperpolarized----1件: 86
1115 mg sodium nitrite inhalation solution1件: Nitrite---1件: 86
12150mg CXA-101件: CXA-10---1件: 86
13171----1件: 86
142-(4-[5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy)-N-(methylsulfonyl)actamide----1件: 86
152-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl) acetamide1件: Acetamide---1件: 86
1620 mg sildenafil citrate by mouth1件: Sildenafil2件: D02229 ,
D08514 		1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
1720 mg/ml Treprostinil1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
1825% MTD sodium nitrite inhalation solution1件: Nitrite---1件: 86
19400 mg BIA 5-10581件: BIA---1件: 86
2045 mg sodium nitrite inhalation solution1件: Nitrite---1件: 86
214AU76----1件: 86
2266215-101----1件: 86
236R-BH41件: Sapropterin1件: D08505 --3件: 86, 124, 240
2475mg CXA-101件: CXA-10---1件: 86
2590 mg sodium nitrite inhalation solution1件: Nitrite---1件: 86
26: 2-{4-[(5,6-difenilpirazin-2-yl)(isopropil)amino]butoxi}-N-----1件: 86
27[11C]-GSK2256098 500 MBq1件: GSK2256098---1件: 86
28[18F] FES----1件: 86
29[18F]Fluoro-2-deoxy-2-D-glucose2件: D-glucose,
Dextrose, unspecified form		1件: D00009 --2件: 86, 88
30ABI-009, nab-rapamycin, albumin-bound rapamycin1件: Sirolimus1件: D00753 1件: MTOR 💬51件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬1件: 86
31Access program - sildenafil citrate, Viagra, Revatio1件: Sildenafil2件: D02229 ,
D08514 		1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
32ACE-011----1件: 86
33Acetamide1件: Acetamide---2件: 86, 154
34Acetaminophen1件: Acetaminophen1件: D00217 2件: PTGS1,
PTGS2 💬		23件: Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬16件: 11, 13, 34, 35, 46, 49, 51, 70, 86, 96, 222, 231, 256, 271, 300, 337
35Acetate1件: Acetate---43件: 1, 2, 6, 10, 13, 35, 40, 46, 49, 51, 60, 64, 67, 70, 71, 73, 75, 76, 78, 79, 81, 83, 85, 86, 88, 90, 96, 97, 113, 145, 156, 162, 171, 206, 222, 224, 225, 227, 235, 265, 288, 298, 299
36ACT - 064992----1件: 86
37ACT-050089----1件: 86
38ACT-050089 (Ro 61-0612)----1件: 86
39ACT-064992----5件: 51, 85, 86, 88, 210
40ACT-064992 / JNJ-67896062----1件: 86
41ACT-064992/ JNJ-67896062----1件: 86
42ACT-064992D----1件: 86
43ACT-178418----1件: 86
44ACT-293987----3件: 51, 86, 88
45ACT-293987 (NS-304)----1件: 86
46ACT-385781A----1件: 86
47ACT-385781A (Actelion Epoprostenol)1件: Epoprostenol2件: D00106 ,
D01337 		1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
48ActRIIA-IgG1Fc----1件: 86
49Adcirca1件: Tadalafil1件: D02008 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
50ADCIRCA 20 mg film-coated tablets1件: Tadalafil1件: D02008 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
51Adcirca®1件: Tadalafil1件: D02008 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
52Adempas1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬		11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬5件: 51, 86, 88, 225, 299
53Adempas (active agent riociguat)1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬		11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬2件: 86, 88
54Adempas (Riociguat, BAY63-2521)1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬		11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬2件: 86, 88
55ADEMPAS - 0,5 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PP/ALU) - 42 COMPRESSE1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬		11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86
56ADEMPAS - 1 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PP/ALU) - 42 COMPRESSE1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬		11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬2件: 51, 86
57ADEMPAS - 1,5 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PP/ALU) - 42 COMPRESSE1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬		11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬2件: 51, 86
58ADEMPAS - 2 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PP/ALU) - 42 COMPRESSE1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬		11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬2件: 51, 86
59ADEMPAS - 2,5 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PP/ALU) - 42 COMPRESSE1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬		11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬2件: 51, 86
60Adempas 0.5 mg1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬		11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬2件: 86, 299
61Adempas 0.5 mg Film Coated Tablet1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬		11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86
62Adempas 1 mg Film Coated Tablet1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬		11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86
63Adempas 1.0 mg1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬		11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬2件: 86, 299
64Adempas 1.5 mg1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬		11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86
65Adempas 1.5 mg Film Coated Tablet1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬		11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86
66Adempas 2 mg Film Coated Tablet1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬		11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86
67Adempas 2.0 mg1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬		11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬2件: 86, 299
68Adempas 2.5 mg1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬		11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86
69Adempas 2.5 mg Film Coated Tablet1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬		11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86
70Adempas®1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬		11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬2件: 86, 88
71Adempas® 0.5 mg film-coated tablets1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬		11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86
72Adempas® 1.0 mg film-coated tablets1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬		11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86
73Adempas® 1.5 mg film-coated tablets1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬		11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86
74Adempas® 2.0 mg film-coated tablets1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬		11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86
75Adempas® 2.5 mg film-coated tablets1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬		11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86
76Adempas¿ 0.5 mg compressa rivestita con film1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬		11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86
77Adempas¿ 1.01件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬		11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86
78Adempas¿ 1.5 mg1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬		11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86
79Adempas¿ 2.0 mg1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬		11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86
80Adempas¿ 2.5 mg1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬		11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86
81Adipose derived mesenchymal stem cells----1件: 86
82AER-901 Solution for Nebulization----1件: 86
83Aerosolized iloprost1件: Iloprost1件: D02721 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
84AIR001----1件: 86
85AIR001 (sodium nitrite inhalation solution)1件: Nitrite---1件: 86
86AIR001 Inhalation Solution----1件: 86
87AIR001 Inhalation Solution (Expansion arm)----1件: 86
88AL----10件: 5, 7, 13, 28, 51, 67, 86, 97, 114, 127
89Albuterol1件: Salbutamol1件: D02147 1件: ADRB2 💬9件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬8件: 12, 13, 86, 89, 113, 231, 256, 299
90Albuterol.1件: Salbutamol1件: D02147 1件: ADRB2 💬9件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
91Allogeneic Human Cardiosphere-Derived Stem Cells----1件: 86
92Ambrisentan1件: Ambrisentan1件: D07077 1件: EDNRA 💬7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬7件: 51, 84, 85, 86, 88, 210, 211
93Ambrisentan - high dose1件: Ambrisentan1件: D07077 1件: EDNRA 💬7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
94Ambrisentan - low dose1件: Ambrisentan1件: D07077 1件: EDNRA 💬7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
95Ambrisentan 5 mg film-coated tablets1件: Ambrisentan1件: D07077 1件: EDNRA 💬7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
96Ambrisentan 5mg film-coated tablets [marketed product]1件: Ambrisentan1件: D07077 1件: EDNRA 💬7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
97Ambrisentan plus Spironolactone2件: Ambrisentan,
Spironolactone		2件: D00443 ,
D07077 		2件: EDNRA,
NR3C2 💬		8件: Aldosterone-regulated sodium reabsorption, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
98Ambrisentan Tablet1件: Ambrisentan1件: D07077 1件: EDNRA 💬7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
99Ammonia1件: Ammonia1件: D02916 --3件: 86, 88, 296
100AMN107----2件: 34, 86
101Anakinra1件: Anakinra1件: D02934 2件: IL1R1,
IL1R2 💬		15件: Amoebiasis, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, MAPK signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Pathogenic Escherichia coli infection, Prostate cancer, Shigellosis, Th17 cell differentiation, Transcriptional misregulation in cancer 💬17件: 2, 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 84, 86, 97, 106, 107, 299
102ANASTROZOLE1件: Anastrozole1件: D00960 1件: CYP19A1 💬3件: Metabolic pathways, Ovarian steroidogenesis, Steroid hormone biosynthesis 💬3件: 78, 86, 193
103Angiotensin1件: Angiotensin II2件: D00150 ,
D02014 		2件: AGTR1,
AGTR2 💬		16件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬7件: 17, 19, 46, 66, 86, 222, 224
104Apabetalone1件: Apabetalone1件: D11131 4件: BRD2,
BRD3,
BRD4,
BRDT 💬		-1件: 86
105APD811----1件: 86
106Apelin----1件: 86
107AR392830----1件: 86
108Aspirin1件: Acetylsalicylic acid1件: D00109 2件: PTGS1,
PTGS2 💬		23件: Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬12件: 13, 22, 34, 46, 49, 51, 58, 86, 113, 158, 210, 231
109Assigned pulmonary hypertension medication----1件: 86
110Autologous EPCs transfected----1件: 86
111Autologous EPCs transfected with human eNOS----1件: 86
112AV-1011件: AV-101---2件: 6, 86
113Aviptadil1件: Aviptadil1件: D12127 --5件: 49, 51, 84, 85, 86
114Axially Oscillating Sphere dry powder inhaler (AOS DPI)----1件: 86
115AZD4831----1件: 86
116B-lines SE----3件: 58, 86, 215
117Bardoxolone1件: Bardoxolone1件: D09584 --7件: 66, 67, 84, 85, 86, 218, 222
118Bardoxolone methyl2件: Bardoxolone,
Bardoxolone methyl		2件: D09584 ,
D09585 		--7件: 66, 67, 84, 85, 86, 218, 222
119Bardoxolone methyl capsules2件: Bardoxolone,
Bardoxolone methyl		2件: D09584 ,
D09585 		--4件: 66, 67, 86, 222
120BARDOXOLONE METHYL, CDDO-Me, CDDO-Methyl Ester, NSC 713200, Chemical Name: Oleana-1,9(11)-dien-28-oic acid, 2-cyano-3,12-dioxo-, methyl ester2件: Bardoxolone,
Bardoxolone methyl		2件: D09584 ,
D09585 		--1件: 86
121BAY 63-2521----2件: 86, 88
122BAY 63-2521 0.06 %----1件: 86
123BAY 63-2521 0.3 %----1件: 86
124BAY 63-2521 coated tablets 0.5 mg----2件: 86, 88
125BAY 63-2521 coated tablets 1 mg----2件: 86, 88
126BAY 63-2521 coated tablets 1.5 mg----2件: 86, 88
127BAY 63-2521 coated tablets 2 mg----2件: 86, 88
128BAY 63-2521 coated tablets 2.5 mg----2件: 86, 88
129BAY 63-2521 IR tablets 0.5 mg----1件: 86
130BAY 63-2521 IR tablets 1 mg----1件: 86
131BAY 63-2521 IR tablets 1.0 mg----1件: 86
132BAY 63-2521 IR tablets 1.5 mg----1件: 86
133BAY 63-2521 IR tablets 2.0 mg----1件: 86
134BAY 63-2521 IR tablets 2.5 mg----1件: 86
135BAY 63-2521 Tablet----1件: 86
136BAY 63-2521 tablets 0.5 mg----2件: 86, 88
137BAY 63-2521 tablets 1 mg----2件: 86, 88
138BAY 63-2521 tablets 1.5 mg----2件: 86, 88
139BAY 63-2521 tablets 2 mg----2件: 86, 88
140BAY 63-2521 tablets 2.5 mg----2件: 86, 88
141Bay Q 6256----1件: 86
142BAY1237592----2件: 86, 88
143BAY63-2521----3件: 51, 86, 299
144Beetroot juice----1件: 86
145Benzbromaron----1件: 86
146Benzbromaron AL----1件: 86
147BENZBROMARONE1件: Benzbromarone1件: D01056 1件: SLC22A12 💬-1件: 86
148Beraprost1件: Beraprost1件: D02720 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
149Beraprost Sodium1件: Beraprost1件: D02720 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
150Beraprost Sodium 314d Modified Release Tablets1件: Beraprost1件: D02720 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
151Beraprost Sodium Modified Release1件: Beraprost1件: D02720 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
152Bevacizumab1件: Bevacizumab1件: D06409 1件: VEGFA 💬24件: AGE-RAGE signaling pathway in diabetic complications, Bladder cancer, Calcium signaling pathway, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, EGFR tyrosine kinase inhibitor resistance, Fluid shear stress and atherosclerosis, Focal adhesion, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, MicroRNAs in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, VEGF signaling pathway 💬9件: 13, 34, 85, 86, 87, 89, 227, 280, 331
153BH4----5件: 51, 86, 124, 240, 299
154BIA1件: BIA---2件: 6, 86
155BIA 5-10581件: BIA---1件: 86
156BIA-5-10581件: BIA---1件: 86
157Biological DMARDs----2件: 86, 107
158BISOPROLOL1件: Bisoprolol2件: D00634 ,
D02342 		1件: ADRB1 💬11件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬3件: 67, 86, 113
159Blood test----6件: 36, 51, 86, 113, 162, 299
160Bosentan1件: Bosentan2件: D01227 ,
D07538 		2件: EDNRA,
EDNRB 💬		9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬11件: 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212
161Bosentan administration1件: Bosentan2件: D01227 ,
D07538 		2件: EDNRA,
EDNRB 💬		9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
162Bosentan and Sildenafil2件: Bosentan,
Sildenafil		4件: D01227 ,
D02229 ,
D07538 ,
D08514 		3件: EDNRA,
EDNRB,
PDE5A 💬		11件: Calcium signaling pathway, Melanogenesis, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Purine metabolism, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
163BOSENTAN MONOHIDRATO1件: Bosentan2件: D01227 ,
D07538 		2件: EDNRA,
EDNRB 💬		9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
164Bosentan monohydrat1件: Bosentan2件: D01227 ,
D07538 		2件: EDNRA,
EDNRB 💬		9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
165BOSENTAN MONOHYDRATE1件: Bosentan2件: D01227 ,
D07538 		2件: EDNRA,
EDNRB 💬		9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬4件: 51, 84, 86, 88
166Bosentan, Ambrisentan2件: Ambrisentan,
Bosentan		3件: D01227 ,
D07077 ,
D07538 		2件: EDNRA,
EDNRB 💬		9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
167BPS-314d-MR----1件: 86
168BPS-MR----1件: 86
169Breelib nebulizer----1件: 86
170Bromure d'Ipratropium1件: Ipratropium1件: D02212 5件: CHRM1,
CHRM2,
CHRM3,
CHRM4,
CHRM5 💬		13件: Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬1件: 86
171BSF 208075----1件: 86
172BSF 208075 or LU 208075----1件: 86
173C07AB07----1件: 86
174C225----2件: 51, 86
175Capsaicin1件: Capsaicin1件: D00250 1件: TRPV1 💬2件: Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬5件: 2, 6, 19, 86, 226
176Captopril1件: Captopril1件: D00251 1件: ACE 💬6件: Chagas disease, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Renin secretion, Renin-angiotensin system 💬2件: 17, 86
177Carbon1件: Activated charcoal---9件: 6, 46, 50, 51, 85, 86, 96, 97, 298
178Carbon monoxide2件: Activated charcoal,
Carbon monoxide		1件: D09706 --3件: 85, 86, 298
179Carnitine1件: Levocarnitine3件: D02030 ,
D02176 ,
D04713 		--9件: 5, 13, 58, 86, 96, 97, 265, 298, 316
180Carvedilol1件: Carvedilol2件: D00255 ,
D03415 		5件: ADRA1A,
ADRA1B,
ADRA1D,
ADRB1,
ADRB2 💬		13件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬5件: 6, 57, 86, 113, 210
181Cetuximab1件: Cetuximab1件: D03455 1件: EGFR 💬48件: Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Coronavirus disease - COVID-19, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Endometrial cancer, Epithelial cell signaling in Helicobacter pylori infection, ErbB signaling pathway, Estrogen signaling pathway, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH signaling pathway, HIF-1 signaling pathway, Hepatitis C, Hepatocellular carcinoma, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, Non-small cell lung cancer, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Shigellosis 💬5件: 34, 51, 86, 89, 331
182Chlorhexidine1件: Chlorhexidine4件: D00858 ,
D01345 ,
D03463 ,
D07668 		--2件: 86, 299
183Cialis1件: Tadalafil1件: D02008 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬2件: 51, 86
184Cialis 10 mg film-coated tablets1件: Tadalafil1件: D02008 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬2件: 86, 113
185Cialis 2.5 mg film-coated tablets1件: Tadalafil1件: D02008 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬2件: 86, 113
186CIALIS 20 mg comprimidos recubiertos con película1件: Tadalafil1件: D02008 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
187Cialis 20 mg film-coated tablets1件: Tadalafil1件: D02008 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬2件: 86, 113
188Cialis 5 mg film-coated tablets1件: Tadalafil1件: D02008 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬2件: 86, 113
189Cicletanine1件: Cicletanine1件: D03487 --1件: 86
190Cicletanine hydrochloride1件: Cicletanine1件: D03487 --1件: 86
191Citrulline1件: Citrulline1件: D07706 --2件: 86, 113
192CJNJ-68150420-ZZZ-G001 (ACT- 064992D)----1件: 86
193CJNJ-68150420-ZZZ-G001 (ACT-064992D)----1件: 86
194CJNJ-68150420-ZZZ-G001(ACT-064992D)----1件: 86
195Clopidogrel1件: Clopidogrel4件: D00769 ,
D07729 ,
D10823 ,
D10824 		1件: P2RY12 💬1件: Platelet activation 💬2件: 49, 86
196Coenzyme Q-101件: Ubidecarenone1件: D01065 --1件: 86
197Coenzyme Q-10 in Normal Control subjects1件: Ubidecarenone1件: D01065 --1件: 86
198Coenzyme Q-10 in Pulmonary Hypertension subjects1件: Ubidecarenone1件: D01065 --1件: 86
199Combination Product:----1件: 86
200Combination Product: Implantable System for Remodulin (treprostinil)1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
201Combination Product: Treprostinil via implanted pump1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
202Commercial Ventavis® (iloprost)1件: Iloprost1件: D02721 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
203Conivaptan1件: Conivaptan2件: D01236 ,
D07748 		2件: AVPR1A,
AVPR2 💬		5件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vascular smooth muscle contraction, Vasopressin-regulated water reabsorption 💬1件: 86
204Conventional drug therapy(expectorant,bronchodilator)----1件: 86
205Coronary flow reserve SE----3件: 58, 86, 215
206CosmoFer----3件: 86, 96, 97
207Crono Five ambulatory pump----1件: 86
208CS1 Administration----1件: 86
209Current marketed FLOLAN (epoprostenol sodium)1件: Epoprostenol2件: D00106 ,
D01337 		1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
210CXA-101件: CXA-10---2件: 86, 222
211D-glucose1件: D-glucose1件: D00009 --3件: 49, 86, 88
212D.3.6.2 - dose massima specificare: giornaliera----1件: 86
213DHEA1件: Prasterone1件: D08409 3件: AR,
ESR1,
ESR2 💬		12件: Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬3件: 49, 86, 96
214DHEA tablet1件: Prasterone1件: D08409 3件: AR,
ESR1,
ESR2 💬		12件: Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬1件: 86
215Diagnostic Test: Cardiac MRI (Gadolinium enhanced)1件: Gadolinium---1件: 86
216Diagnostic Test: CMRI----2件: 51, 86
217Diagnostic Test: Endogenous thrombin potential1件: Thrombin1件: D00090 --2件: 86, 88
218Diagnostic Test: Light transmission aggregometry----2件: 86, 88
219Diagnostic Test: PET-CT Imaging with [89Zr]-bevacizumab1件: Bevacizumab1件: D06409 1件: VEGFA 💬24件: AGE-RAGE signaling pathway in diabetic complications, Bladder cancer, Calcium signaling pathway, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, EGFR tyrosine kinase inhibitor resistance, Fluid shear stress and atherosclerosis, Focal adhesion, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, MicroRNAs in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, VEGF signaling pathway 💬1件: 86
220Diagnostic Test: Platelet function analyzer-100----2件: 86, 88
221Diagnostic Test: Rotational thromboelastometry----2件: 86, 88
222Diastolic function SE----3件: 58, 86, 215
223Dichloroacetate1件: Dichloroacetic acid---1件: 86
224Dichloroacetate Sodium1件: Dichloroacetic acid---1件: 86
225Dietanolamina de treprostinilo1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
226Diltiazem1件: Diltiazem3件: D00616 ,
D03830 ,
D07845 		4件: CACNA1C,
CACNA1D,
CACNA1F,
CACNA1S 💬		37件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬3件: 51, 58, 86
227Diltiazem Hydrochloride1件: Diltiazem3件: D00616 ,
D03830 ,
D07845 		4件: CACNA1C,
CACNA1D,
CACNA1F,
CACNA1S 💬		37件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
228DIMETHYL FUMARATE1件: Dimethyl fumarate1件: D03846 1件: KEAP1 💬6件: Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Parkinson disease, Pathways in cancer, Ubiquitin mediated proteolysis 💬4件: 13, 51, 86, 296
229Dimethyl Fumarate (DMF)1件: Dimethyl fumarate1件: D03846 1件: KEAP1 💬6件: Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Parkinson disease, Pathways in cancer, Ubiquitin mediated proteolysis 💬3件: 13, 51, 86
230Diphenhydramine1件: Diphenhydramine6件: D00300 ,
D00669 ,
D02419 ,
D03285 ,
D03360 ,
D03854 		1件: HRH1 💬3件: Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬10件: 11, 13, 49, 51, 70, 86, 96, 222, 256, 300
231Duo-Therapy with Sildenafil + Bosentan2件: Bosentan,
Sildenafil		4件: D01227 ,
D02229 ,
D07538 ,
D08514 		3件: EDNRA,
EDNRB,
PDE5A 💬		11件: Calcium signaling pathway, Melanogenesis, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Purine metabolism, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
232EFI/ACT-385781A----1件: 86
233Elafin1件: Elafin---1件: 86
234EndoPAT measurement----1件: 86
235Endothelin receptor antagonist therapy----1件: 86
236Endothelin Receptor Antagonists----1件: 86
237Endothelin-3----1件: 86
238ENOS transfected EPCs will be delivered via a PA line----1件: 86
239Epicatechin1件: Epicatechin---2件: 86, 113
240EPOPROSTENOL1件: Epoprostenol2件: D00106 ,
D01337 		1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
241Epoprostenol for injection1件: Epoprostenol2件: D00106 ,
D01337 		1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
242EPOPROSTENOL SODICO1件: Epoprostenol2件: D00106 ,
D01337 		1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
243EPOPROSTENOL SODIUM1件: Epoprostenol2件: D00106 ,
D01337 		1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
244Epoprostenol-Actelion1件: Epoprostenol2件: D00106 ,
D01337 		1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
245Epoprostenolo per iniezione----1件: 86
246Equal----5件: 6, 13, 67, 86, 230
247ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan)4件: Bosentan,
Macitentan,
Sildenafil,
Tadalafil		6件: D01227 ,
D02008 ,
D02229 ,
D07538 ,
D08514 ,
D10135 		3件: EDNRA,
EDNRB,
PDE5A 💬		11件: Calcium signaling pathway, Melanogenesis, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Purine metabolism, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
248ERA as specific PAH treatment----1件: 86
249Erbitux1件: Cetuximab1件: D03455 1件: EGFR 💬48件: Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Coronavirus disease - COVID-19, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Endometrial cancer, Epithelial cell signaling in Helicobacter pylori infection, ErbB signaling pathway, Estrogen signaling pathway, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH signaling pathway, HIF-1 signaling pathway, Hepatitis C, Hepatocellular carcinoma, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, Non-small cell lung cancer, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Shigellosis 💬2件: 51, 86
250Esomeprazole1件: Esomeprazole4件: D01984 ,
D04056 ,
D07917 ,
D09339 		2件: ATP4A,
ATP4B 💬		4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬8件: 13, 46, 86, 98, 107, 113, 298, 299
251ESR-specific PET scan----1件: 86
252Esuberaprost----1件: 86
253Eutonic Treprostinil Solution1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
254Famotidine1件: Famotidine1件: D00318 1件: HRH2 💬3件: Calcium signaling pathway, Gastric acid secretion, Neuroactive ligand-receptor interaction 💬6件: 6, 46, 86, 98, 107, 300
255Famotidine 20 MG1件: Famotidine1件: D00318 1件: HRH2 💬3件: Calcium signaling pathway, Gastric acid secretion, Neuroactive ligand-receptor interaction 💬1件: 86
256FDC macitentan/tadalafil2件: Macitentan,
Tadalafil		2件: D02008 ,
D10135 		3件: EDNRA,
EDNRB,
PDE5A 💬		11件: Calcium signaling pathway, Melanogenesis, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Purine metabolism, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
257Ferinject----2件: 86, 299
258Ferinject or CosmoFer----1件: 86
259FERRIC CARBOXYMALTOSE1件: Ferric carboxymaltose1件: D08920 --4件: 86, 96, 97, 299
260Ferricarboxymaltose----1件: 86
261FK506 level 2-3 ng/ml----1件: 86
262FK506 level 3-5 ng/ml----1件: 86
263FK506 level < 2 ng/ml----1件: 86
264Flolan1件: Epoprostenol2件: D00106 ,
D01337 		1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
265FLOLAN injection with currently marketed diluent1件: Epoprostenol2件: D00106 ,
D01337 		1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
266FLOLAN injection with reformulated diluent1件: Epoprostenol2件: D00106 ,
D01337 		1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
267FLOLAN TM and Glycine Diluent2件: Epoprostenol,
Glycine		3件: D00011 ,
D00106 ,
D01337 		1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
268Flolan®1件: Epoprostenol2件: D00106 ,
D01337 		1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
269FLOLAN™ and Glycine Diluent2件: Epoprostenol,
Glycine		3件: D00011 ,
D00106 ,
D01337 		1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
270FLUOXETINE1件: Fluoxetine2件: D00326 ,
D00823 		1件: SLC6A4 💬2件: Serotonergic synapse, Synaptic vesicle cycle 💬4件: 13, 17, 78, 86
271Fulvestrant1件: Fulvestrant1件: D01161 2件: ESR1,
ESR2 💬		10件: Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬1件: 86
272G04BE03----1件: 86
273G04BE03- Sildenafil - sildenafil (citrato)1件: Sildenafil2件: D02229 ,
D08514 		1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
274G04BE08----1件: 86
275Gadolinium1件: Gadolinium---6件: 13, 34, 46, 58, 65, 86
276GB002----1件: 86
277GB002 (seralutinib)----1件: 86
278GB002 Capsules----1件: 86
279Generic Dry Powder Inhaler----1件: 86
280GLIVEC1件: Imatinib2件: D01441 ,
D08066 		3件: ABL1,
KIT,
PDGFRA 💬		32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬2件: 51, 86
281GLIVEC 100 mg comprimidos recubiertos con película1件: Imatinib2件: D01441 ,
D08066 		3件: ABL1,
KIT,
PDGFRA 💬		32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬2件: 34, 86
282Glivec 100 mg Filmtabletten1件: Imatinib2件: D01441 ,
D08066 		3件: ABL1,
KIT,
PDGFRA 💬		32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬2件: 51, 86
283Glivec 100 mg Hartkapsel1件: Imatinib2件: D01441 ,
D08066 		3件: ABL1,
KIT,
PDGFRA 💬		32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬1件: 86
284Glivec®1件: Imatinib2件: D01441 ,
D08066 		3件: ABL1,
KIT,
PDGFRA 💬		32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬1件: 86
285Glivec® 100 mg Filmtabletten1件: Imatinib2件: D01441 ,
D08066 		3件: ABL1,
KIT,
PDGFRA 💬		32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬1件: 86
286Glucose1件: Dextrose, unspecified form---15件: 2, 6, 13, 49, 50, 65, 75, 86, 88, 96, 160, 195, 254, 257, 299
287GLYCINE1件: Glycine1件: D00011 --5件: 35, 60, 86, 226, 299
288GMA301 Injection----1件: 86
289Gold1件: Gold---43件: 2, 5, 6, 13, 17, 34, 35, 46, 49, 50, 53, 58, 65, 68, 76, 84, 86, 91, 93, 95, 96, 97, 98, 113, 137, 158, 162, 171, 193, 218, 222, 224, 227, 230, 235, 271, 291, 294, 296, 298, 299, 310, 318
290Gradient----4件: 58, 86, 149, 215
291GS-4997 18 mg----1件: 86
292GS-4997 2 mg----1件: 86
293GS-4997 6 mg----1件: 86
294GSK1325760----2件: 86, 88
295GSK1325760A----1件: 86
296GSK22560981件: GSK2256098---1件: 86
297GSK2586881----1件: 86
298HGP1206----1件: 86
299Hydroxyurea1件: Hydroxyurea1件: D00341 1件: RRM2 💬6件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism, p53 signaling pathway 💬8件: 3, 13, 19, 20, 65, 85, 86, 284
300Hyperpolarized 129Xe----1件: 86
301HypotonicTreprostinil Solution----1件: 86
302I-Neb AAD system----1件: 86
303I.v. selexipag1件: Selexipag1件: D09994 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
304Ifetroban1件: Ifetroban1件: D04500 1件: TBXA2R 💬3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Platelet activation 💬3件: 51, 86, 113
305Ilomedin 20----1件: 86
306Ilomedin 20 [20 µg / ml]----1件: 86
307Iloprost1件: Iloprost1件: D02721 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬4件: 51, 84, 85, 86
308Iloprost (5 µg)1件: Iloprost1件: D02721 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
309Iloprost (Ventavis BAYQ6256)1件: Iloprost1件: D02721 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
310Iloprost (Ventavis inhaled, BAYQ6256)1件: Iloprost1件: D02721 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
311Iloprost (Ventavis, BAYQ 6256)1件: Iloprost1件: D02721 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
312Iloprost (Ventavis, BAYQ6256)1件: Iloprost1件: D02721 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
313Iloprost (Ventavis®)1件: Iloprost1件: D02721 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
314Iloprost Inhalation Solution (Ventavis)1件: Iloprost1件: D02721 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬2件: 85, 86
315Iloprost PD-151件: Iloprost1件: D02721 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
316Iloprost PD-61件: Iloprost1件: D02721 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
317Iloprost,(Ventavis, BAYQ6256)1件: Iloprost1件: D02721 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
318Imatinib1件: Imatinib2件: D01441 ,
D08066 		3件: ABL1,
KIT,
PDGFRA 💬		32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162
319IMATINIB MESILATE1件: Imatinib2件: D01441 ,
D08066 		3件: ABL1,
KIT,
PDGFRA 💬		32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬3件: 13, 86, 88
320Imatinib Mesylate1件: Imatinib2件: D01441 ,
D08066 		3件: ABL1,
KIT,
PDGFRA 💬		32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬5件: 13, 28, 34, 51, 86
321Inhaled dry powder treprostinil (LIQ861)1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
322Inhaled Iloprost (5 µg)1件: Iloprost1件: D02721 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
323Inhaled iloprost (Ventavis, BAYQ6256)1件: Iloprost1件: D02721 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
324Inhaled Nitric Oxide1件: Nitric Oxide1件: D00074 --2件: 85, 86
325Inhaled nitric oxide & INOpulse delivery1件: Nitric Oxide1件: D00074 --1件: 86
326Inhaled nitric oxide 75 mcg/kg IBW/hr1件: Nitric Oxide1件: D00074 --2件: 85, 86
327Inhaled NO with pulsed delivery----1件: 86
328Inhaled prostacyclin1件: Epoprostenol2件: D00106 ,
D01337 		1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
329Inhaled Treprostinil1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬3件: 84, 85, 86
330INO----2件: 85, 86
331Intestinal microbiota transplant (IMT)----1件: 86
332Intravenous administration of ferric carboxymaltose1件: Ferric carboxymaltose1件: D08920 --1件: 86
333Intravenous Treprostinil1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
334Intravenous/Subcutaneous Treprostinil1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
335Ipratropium1件: Ipratropium1件: D02212 5件: CHRM1,
CHRM2,
CHRM3,
CHRM4,
CHRM5 💬		13件: Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬2件: 6, 86
336Iron supplement----1件: 86
337JNJ-67896049----1件: 86
338JNJ-67896049 (ACT-293987)----1件: 86
339JNJ-67896062 / ACT-064992----2件: 86, 88
340JNJ-67896062/ ACT-064992----2件: 86, 88
341JTT-251----1件: 86
342KAR5585 Capsules----1件: 86
343L-Carnitine1件: Levocarnitine3件: D02030 ,
D02176 ,
D04713 		--7件: 13, 86, 96, 97, 265, 298, 316
344L-Citrulline Malate1件: Citrulline1件: D07706 --1件: 86
345L606 (Liposomal Treprostinil) Inhalation Solution 51ug1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
346L606 Inhalation System----1件: 86
347Left ventricular contractile reserve SE----3件: 58, 86, 215
348Left ventricular outflow tract gradient SE----3件: 58, 86, 215
349Levitra1件: Vardenafil3件: D02731 ,
D03260 ,
D08668 		1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬2件: 13, 86
350Lidocaine1件: Lidocaine3件: D00358 ,
D02086 ,
D08127 		5件: SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A 💬		3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬12件: 6, 13, 34, 46, 51, 70, 86, 107, 168, 226, 231, 256
351LIQ861 100 µg----1件: 86
352LIQ861 106 µg----1件: 86
353LIQ861 25 µg----1件: 86
354LIQ861 26.5 µg----1件: 86
355LIQ861 50 µg----1件: 86
356LIQ861 53 µg----1件: 86
357LIQ861 75 µg----1件: 86
358LIQ861 79.5 µg----1件: 86
359LIQ861 Inhaled Treprostinil1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
360LISURIDE1件: Lisuride2件: D01462 ,
D08132 		3件: DRD2,
DRD3,
DRD4 💬		8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬2件: 6, 86
361Lloprost(Ventavis,BAYQ6252, 10 µg/mL)1件: Iloprost1件: D02721 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
362Lloprost(Ventavis,BAYQ6252, 20 µg/mL)1件: Iloprost1件: D02721 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
363LTP001----1件: 86
364LY450190----1件: 86
365Macitentan1件: Macitentan1件: D10135 2件: EDNRA,
EDNRB 💬		9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬5件: 51, 85, 86, 88, 210
366Macitentan (ACT-064992)1件: Macitentan1件: D10135 2件: EDNRA,
EDNRB 💬		9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
367Macitentan 10 mg1件: Macitentan1件: D10135 2件: EDNRA,
EDNRB 💬		9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬3件: 51, 86, 88
368Macitentan 10 mg tablet, once daily.1件: Macitentan1件: D10135 2件: EDNRA,
EDNRB 💬		9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
369Macitentan 37.5 mg1件: Macitentan1件: D10135 2件: EDNRA,
EDNRB 💬		9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
370Macitentan 75 mg1件: Macitentan1件: D10135 2件: EDNRA,
EDNRB 💬		9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
371MACITENTAN COMPRESSE1件: Macitentan1件: D10135 2件: EDNRA,
EDNRB 💬		9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬2件: 86, 88
372Macitentan Group1件: Macitentan1件: D10135 2件: EDNRA,
EDNRB 💬		9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
373MACITENTAN TABLETS1件: Macitentan1件: D10135 2件: EDNRA,
EDNRB 💬		9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬2件: 86, 88
374MD-711----1件: 86
375Medical air2件: Medical air,
Oxygen		1件: D00003 --3件: 85, 86, 193
376Metformin1件: Metformin2件: D00944 ,
D04966 		2件: PRKAA1,
PRKAA2 💬		20件: AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬24件: 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301
377Methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo----1件: 86
378Methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo [3,4-b]pyridine-3-yl]-5-pyrimidinyl(methyl)carb----2件: 86, 88
379Methyl [4,6-diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]meth----2件: 86, 88
380Methylprednisolone1件: Methylprednisolone6件: D00407 ,
D00751 ,
D00979 ,
D05000 ,
D05001 ,
D05002 		1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬48件: 2, 6, 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
381MHealth Intervention----1件: 86
382Mitral regurgitation SE----3件: 58, 86, 215
383MK-4836----1件: 86
384MK-5475----1件: 86
385MK-8892----1件: 86
386MONITOR1件: Methamidophos---20件: 2, 11, 13, 19, 28, 46, 49, 58, 65, 70, 81, 85, 86, 98, 113, 118, 129, 298, 299, 300
387Mono-Therapy with Sildenafil1件: Sildenafil2件: D02229 ,
D08514 		1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
388Morphine1件: Morphine3件: D00842 ,
D02271 ,
D08233 		1件: OPRM1 💬3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 💬6件: 36, 46, 70, 85, 86, 298
389MORPHINE SULFATE2件: Morphine,
Sulfate ion		3件: D00842 ,
D02271 ,
D08233 		1件: OPRM1 💬3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 💬3件: 46, 85, 86
390Moxifloxacin1件: Moxifloxacin2件: D00874 ,
D08237 		--9件: 2, 6, 46, 49, 85, 86, 113, 240, 299
391Moxifloxacin 400 mg1件: Moxifloxacin2件: D00874 ,
D08237 		--1件: 86
392MultiHance1件: Gadobenic acid2件: D04283 ,
D08018 		--2件: 86, 88
393Nebulized combination ipratropium bromide with salbutamol2件: Ipratropium,
Salbutamol		2件: D02147 ,
D02212 		6件: ADRB2,
CHRM1,
CHRM2,
CHRM3,
CHRM4,
CHRM5 💬		18件: Adrenergic signaling in cardiomyocytes, Alzheimer disease, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Taste transduction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
394Nebulized ipratropium bromide1件: Ipratropium1件: D02212 5件: CHRM1,
CHRM2,
CHRM3,
CHRM4,
CHRM5 💬		13件: Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬1件: 86
395New thermo stable formulation of epoprostenol sodium1件: Epoprostenol2件: D00106 ,
D01337 		1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
396Nicardipine1件: Nicardipine2件: D00617 ,
D08270 		4件: CACNA1C,
CACNA1D,
CACNA1F,
CACNA1S 💬		37件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬2件: 70, 86
397Nilotinib1件: Nilotinib1件: D08953 4件: ABL1,
KIT,
PDGFRA,
PDGFRB 💬		33件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬5件: 6, 8, 34, 51, 86
398Nilotinib 50 mg1件: Nilotinib1件: D08953 4件: ABL1,
KIT,
PDGFRA,
PDGFRB 💬		33件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬1件: 86
399Nitric Oxide1件: Nitric Oxide1件: D00074 --8件: 46, 85, 86, 98, 210, 251, 294, 299
400Nitric Oxide for inhalation1件: Nitric Oxide1件: D00074 --2件: 86, 299
401Nitric Oxide generated by the GeNO nitrosyl delivery system1件: Nitric Oxide1件: D00074 --1件: 86
402Nitric Oxide plus Oxygen2件: Nitric Oxide,
Oxygen		2件: D00003 ,
D00074 		--1件: 86
403Nitrite1件: Nitrite---3件: 58, 86, 299
404Nitrosyl1件: Nitric Oxide1件: D00074 --1件: 86
405NO----12件: 6, 13, 46, 58, 62, 86, 96, 97, 222, 226, 299, 321
406Non-Biologic DMARDs----3件: 46, 86, 107
407NS-304----3件: 70, 86, 88
408Null----16件: 6, 13, 15, 28, 37, 46, 49, 51, 63, 86, 90, 96, 97, 107, 145, 271
409NX1011----1件: 86
410Observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi4件: Epoprostenol,
Iloprost,
Macitentan,
Selexipag		5件: D00106 ,
D01337 ,
D02721 ,
D09994 ,
D10135 		3件: EDNRA,
EDNRB,
PTGIR 💬		10件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Platelet activation, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
411Olaparib1件: Olaparib1件: D09730 2件: PARP1,
PARP2 💬		5件: Apoptosis, Base excision repair, Diabetic cardiomyopathy, NF-kappa B signaling pathway, Necroptosis 💬2件: 86, 285
412Opsumit1件: Macitentan1件: D10135 2件: EDNRA,
EDNRB 💬		9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬3件: 86, 88, 210
413Opsumit (macitentan)1件: Macitentan1件: D10135 2件: EDNRA,
EDNRB 💬		9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
414Opsumit®1件: Macitentan1件: D10135 2件: EDNRA,
EDNRB 💬		9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬3件: 86, 88, 210
415Oral anticoagulant treatment----1件: 86
416Oral ERA----1件: 86
417Oral Ifetroban1件: Ifetroban1件: D04500 1件: TBXA2R 💬3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Platelet activation 💬2件: 51, 86
418Oral PDE5 inhibitors----1件: 86
419Oral selexipag (Uptravi)1件: Selexipag1件: D09994 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
420Oral sildenafil1件: Sildenafil2件: D02229 ,
D08514 		1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
421Oral treprostinil1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬2件: 51, 86
422Oral treprostinil (UT-15C) Sustained Release Tablets1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
423Ossido Nitrico----1件: 86
424Other: Iloprost (Ventavis inhaled, BAYQ6256)1件: Iloprost1件: D02721 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
425Other: Noninvasive actigraphy monitor1件: Methamidophos---1件: 86
426Other: Oxygen Supplementation1件: Oxygen1件: D00003 --1件: 86
427Other: Standard-of-care----1件: 86
428Other: Standardized meals----1件: 86
429Other: Subacute hypoxic exposures----1件: 86
430Oxygen1件: Oxygen1件: D00003 --20件: 6, 13, 19, 46, 49, 70, 84, 85, 86, 88, 90, 96, 97, 168, 193, 226, 271, 294, 299, 330
431Oxygen supplementation1件: Oxygen1件: D00003 --1件: 86
432Oxygen, liquid1件: Oxygen1件: D00003 --2件: 86, 88
433PADN----1件: 86
434PAH----3件: 49, 53, 86
435PAH medication----1件: 86
436PAH Therapies----1件: 86
437Parenteral Remodulin (treprostinil) injection1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
438PB1046----1件: 86
439PB1046 Subcutaneous Injection----1件: 86
440PB1046, VIP-ELP1-120, Vasomera----1件: 86
441PDE5 inhibitor----1件: 86
442Pemziviptadil (PB1046)----1件: 86
443Pemziviptadil (PB1046) Injection----1件: 86
444PF-004897911件: PF-00489791---1件: 86
445Pioglitazone1件: Pioglitazone2件: D00945 ,
D08378 		1件: PPARG 💬11件: AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬17件: 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299
446Placebo----27件: 3, 5, 6, 13, 14, 37, 40, 46, 49, 50, 51, 53, 63, 66, 67, 79, 85, 86, 88, 96, 97, 140, 144, 149, 226, 271, 276
447PLX-PAD1件: Placental Mesenchymal Stem Cells---1件: 86
448Prednisone1件: Prednisone1件: D00473 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬48件: 2, 6, 11, 13, 14, 19, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 79, 81, 84, 85, 86, 95, 96, 97, 113, 127, 162, 164, 205, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331
449Prostacyclin1件: Epoprostenol2件: D00106 ,
D01337 		1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
450Pulmonary hemodynamics SE----3件: 58, 86, 215
451Puri-Nethol----3件: 86, 96, 97
452Q4W GMA301 IV injections (1000 mg)----1件: 86
453Q4W GMA301 IV injections (300 mg)----1件: 86
454Q4W GMA301 IV injections (600 mg)----1件: 86
455QCC374----1件: 86
456QCC374 0.015 mg----1件: 86
457QCC374 0.06 mg----1件: 86
458QTI571----1件: 86
459Qutenza----1件: 86
460Qutenza (8% capsaicin)1件: Capsaicin1件: D00250 1件: TRPV1 💬2件: Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬1件: 86
461Radiation: PET/CT Scan: Two PET scans using 1. C-11 HED and 2. N-13 Ammonia or rubidium-822件: Ammonia,
Rubidium		1件: D02916 --1件: 86
462RALINEPAG1件: Ralinepag1件: D10725 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
463Ranolazine1件: Ranolazine2件: D05700 ,
D05701 		--6件: 2, 58, 86, 96, 113, 114
464Rapamycin1件: Sirolimus1件: D00753 1件: MTOR 💬51件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬19件: 2, 15, 34, 35, 46, 49, 51, 60, 61, 67, 86, 89, 96, 157, 158, 193, 256, 278, 279
465Rapid Dose Titration Group of Subcutaneous Treprostinil1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
466Recombinant Human Angiotensin-Converting Enzyme 22件: Alunacedase alfa,
Angiotensin II		2件: D00150 ,
D02014 		2件: AGTR1,
AGTR2 💬		16件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86
467Recombinant Human Angiotensin-converting enzyme 2 (ACE2), APN012件: Alunacedase alfa,
Angiotensin II		2件: D00150 ,
D02014 		2件: AGTR1,
AGTR2 💬		16件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86
468Remodulin1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬2件: 86, 88
469Remodulin (treprostinil sodium)1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
470Remodulin® (treprostinil) 1 mg/ml solution for infusion1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
471Remodulin® (treprostinil) 10 mg/ml solution for infusion1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
472Remodulin® (treprostinil) 2.5 mg/ml solution for infusion1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
473Remodulin® (treprostinil) 5 mg/ml solution for infusion1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
474Revatio1件: Sildenafil2件: D02229 ,
D08514 		1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬3件: 85, 86, 113
475Revatio 10 mg/ml powder for oral suspension1件: Sildenafil2件: D02229 ,
D08514 		1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
476Revatio 20 mg film coated tablets1件: Sildenafil2件: D02229 ,
D08514 		1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
477Revatio 20 mg film-coated tablets----1件: 86
478Revatio 20 mg Filmtabletten1件: Sildenafil2件: D02229 ,
D08514 		1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
479REVATIO 20 mg, comprimidos recubiertos con película1件: Sildenafil2件: D02229 ,
D08514 		1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
480Revatio inyectable1件: Sildenafil2件: D02229 ,
D08514 		1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
481Revatio oral1件: Sildenafil2件: D02229 ,
D08514 		1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
482Revatio POS1件: Sildenafil2件: D02229 ,
D08514 		1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
483Revatio Tablets1件: Sildenafil2件: D02229 ,
D08514 		1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
484Revatio ® 20 mg film-coated tablets1件: Sildenafil2件: D02229 ,
D08514 		1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
485Revatio®1件: Sildenafil2件: D02229 ,
D08514 		1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
486Riciguat Group----1件: 86
487Rifampin1件: Rifampicin1件: D00211 --5件: 6, 13, 84, 86, 299
488RIOCIGUAT1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬		11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬6件: 51, 84, 86, 88, 225, 299
489Riociguat (Adempas, BAY63-2521)1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬		11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬4件: 51, 86, 88, 299
490Riociguat (BAY63-2521)1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬		11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86
491Riociguat granules 0.3% for oral application1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬		11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86
492Riociguat Oral Product1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬		11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86
493Riociguat Pill1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬		11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86
494Ritonavir1件: Ritonavir1件: D00427 --3件: 2, 86, 265
495Rituximab1件: Rituximab1件: D02994 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬49件: 6, 11, 13, 14, 17, 19, 35, 36, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 127, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331
496Ro 47-0203----4件: 51, 85, 86, 88
497Ro 47-0203 / ACT-050088----1件: 86
498Ro-47-0203----1件: 86
499Ro-47-0203/029----1件: 86
500Ro47-0203----1件: 86
501Ro47-0203 / ACT-050088----2件: 51, 86
502RoActemra1件: Tocilizumab1件: D02596 1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬11件: 40, 41, 44, 46, 50, 51, 86, 107, 266, 271, 331
503Rodatristat ethyl----1件: 86
504Rodatristat Ethyl 300 mg tablet----1件: 86
505RT234 - vardenafil inhalation powder1件: Vardenafil3件: D02731 ,
D03260 ,
D08668 		1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
506RTA 402----3件: 67, 86, 218
507Rubidium1件: Rubidium---2件: 84, 86
508RVG 33865----1件: 86
509RVT-1201----1件: 86
510Salbutamol1件: Salbutamol1件: D02147 1件: ADRB2 💬9件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬9件: 3, 11, 49, 85, 86, 111, 228, 256, 299
511Saline----10件: 6, 13, 17, 53, 67, 78, 86, 97, 168, 299
512Sapropterin1件: Sapropterin1件: D08505 --3件: 86, 124, 240
513Sapropterin dihydrochloride (6R-BH4)1件: Sapropterin1件: D08505 --1件: 86
514Saquinavir1件: Saquinavir2件: D00429 ,
D01160 		--2件: 86, 265
515Saquinavir and ritonavir2件: Ritonavir,
Saquinavir		3件: D00427 ,
D00429 ,
D01160 		--1件: 86
516Sauerstoff----2件: 86, 88
517Selexipag1件: Selexipag1件: D09994 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬6件: 47, 51, 70, 84, 86, 88
518Selexipag (Uptravi)1件: Selexipag1件: D09994 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
519Selexipag, ACT-293987 (NS-304)1件: Selexipag1件: D09994 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
520Selonsertib1件: Selonsertib1件: D10988 1件: MAP3K5 💬20件: Alcoholic liver disease, Alzheimer disease, Amyotrophic lateral sclerosis, Apoptosis, Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Huntington disease, Lipid and atherosclerosis, MAPK signaling pathway, Neurotrophin signaling pathway, Non-alcoholic fatty liver disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Platinum drug resistance, Protein processing in endoplasmic reticulum, Sphingolipid signaling pathway, Spinocerebellar ataxia, TNF signaling pathway, Thermogenesis, Tight junction 💬1件: 86
521Seralutinib----1件: 86
522Serine1件: Serine1件: D00016 --4件: 2, 6, 86, 96
523Sham O2 (medical air)2件: Medical air,
Oxygen		1件: D00003 --1件: 86
524Sham PADN----1件: 86
525SILDENAF----1件: 86
526Sildenafil1件: Sildenafil2件: D02229 ,
D08514 		1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬17件: 6, 46, 50, 51, 85, 86, 90, 113, 210, 211, 212, 225, 226, 278, 294, 299, 301
527Sildenafil (as citrate)1件: Sildenafil2件: D02229 ,
D08514 		1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
528Sildenafil (REVATIO)1件: Sildenafil2件: D02229 ,
D08514 		1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
529Sildenafil (Revatio) 20 mg TID1件: Sildenafil2件: D02229 ,
D08514 		1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
530Sildenafil 20mg1件: Sildenafil2件: D02229 ,
D08514 		1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬2件: 51, 86
531Sildenafil 20mg and Bosentan 62.5mg2件: Bosentan,
Sildenafil		4件: D01227 ,
D02229 ,
D07538 ,
D08514 		3件: EDNRA,
EDNRB,
PDE5A 💬		11件: Calcium signaling pathway, Melanogenesis, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Purine metabolism, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬2件: 51, 86
532Sildenafil citrate1件: Sildenafil2件: D02229 ,
D08514 		1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬4件: 51, 85, 86, 225
533Sildenafil citrate (UK-92,480)1件: Sildenafil2件: D02229 ,
D08514 		1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
534Sildenafil Filmtabletten1件: Sildenafil2件: D02229 ,
D08514 		1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
535Sildenafil singly or in association with Bosentan2件: Bosentan,
Sildenafil		4件: D01227 ,
D02229 ,
D07538 ,
D08514 		3件: EDNRA,
EDNRB,
PDE5A 💬		11件: Calcium signaling pathway, Melanogenesis, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Purine metabolism, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
536SILDENAFILO1件: Sildenafil2件: D02229 ,
D08514 		1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
537Simvastatin1件: Simvastatin1件: D00434 1件: HMGCR 💬4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬21件: 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310
538Simvastatin 40 mg1件: Simvastatin1件: D00434 1件: HMGCR 💬4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬1件: 86
539Simvastatin 40 mg tablets1件: Simvastatin1件: D00434 1件: HMGCR 💬4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬1件: 86
540Sitaxentan1件: Sitaxentan1件: D07171 1件: EDNRA 💬7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
541Sitaxentan sodium1件: Sitaxentan1件: D07171 1件: EDNRA 💬7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
542Sitaxsentan1件: Sitaxentan1件: D07171 1件: EDNRA 💬7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
543Sitaxsentan alone1件: Sitaxentan1件: D07171 1件: EDNRA 💬7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
544Sitaxsentan and Sildenafil2件: Sildenafil,
Sitaxentan		3件: D02229 ,
D07171 ,
D08514 		2件: EDNRA,
PDE5A 💬		9件: Calcium signaling pathway, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Purine metabolism, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
545SITAXSENTAN SODIUM1件: Sitaxentan1件: D07171 1件: EDNRA 💬7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
546Slow Dose Titration Group of Subcutaneous Treprostinil1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
547SODIUM NITRITE1件: Nitrite---2件: 86, 299
548Sodium Nitrite Inhalation Solution1件: Nitrite---1件: 86
549Sodium tanshinone IIA sulfonate diluted with 5% glucose solution,20mg sildenafil citrate by mouth2件: Dextrose, unspecified form,
Sildenafil		2件: D02229 ,
D08514 		1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
550Sorafenib1件: Sorafenib2件: D06272 ,
D08524 		8件: BRAF,
FLT3,
FLT4,
KDR,
KIT,
PDGFRB,
RAF1,
RET 💬		89件: Acute myeloid leukemia, Alcoholism, Alzheimer disease, Apelin signaling pathway, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bladder cancer, Breast cancer, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Chronic myeloid leukemia, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-small cell lung cancer, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Serotonergic synapse, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, Thyroid cancer, Thyroid hormone signaling pathway, Transcriptional misregulation in cancer, Tuberculosis, VEGF signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway 💬2件: 34, 86
551SOTATERCEPT1件: Sotatercept1件: D09670 1件: ACVR2A 💬4件: Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Signaling pathways regulating pluripotency of stem cells, TGF-beta signaling pathway 💬2件: 86, 284
552Sotatercept - 45 mg/vial1件: Sotatercept1件: D09670 1件: ACVR2A 💬4件: Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Signaling pathways regulating pluripotency of stem cells, TGF-beta signaling pathway 💬1件: 86
553Sotatercept - 60 mg/vial1件: Sotatercept1件: D09670 1件: ACVR2A 💬4件: Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Signaling pathways regulating pluripotency of stem cells, TGF-beta signaling pathway 💬1件: 86
554Spironolactone1件: Spironolactone1件: D00443 1件: NR3C2 💬1件: Aldosterone-regulated sodium reabsorption 💬7件: 58, 67, 86, 113, 210, 218, 225
555Spironolactone and conivaptan2件: Conivaptan,
Spironolactone		3件: D00443 ,
D01236 ,
D07748 		3件: AVPR1A,
AVPR2,
NR3C2 💬		6件: Aldosterone-regulated sodium reabsorption, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vascular smooth muscle contraction, Vasopressin-regulated water reabsorption 💬1件: 86
556Spironolactone captopril carvedilol3件: Captopril,
Carvedilol,
Spironolactone		4件: D00251 ,
D00255 ,
D00443 ,
D03415 		7件: ACE,
ADRA1A,
ADRA1B,
ADRA1D,
ADRB1,
ADRB2,
NR3C2 💬		19件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Aldosterone-regulated sodium reabsorption, Calcium signaling pathway, Chagas disease, Chemical carcinogenesis - receptor activation, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, Dilated cardiomyopathy, Gap junction, Hypertrophic cardiomyopathy, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Renin-angiotensin system, Salivary secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
557STI571----2件: 51, 86
558Subcutaneous and intravenous prostacyclin1件: Epoprostenol2件: D00106 ,
D01337 		1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
559Subcutaneous Treprostinil1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
560Sugar pill----8件: 5, 6, 49, 67, 70, 86, 206, 210
561SULFASALAZINE1件: Sulfasalazine1件: D00448 --6件: 46, 86, 94, 107, 270, 271
562Sulfate1件: Sulfate ion---27件: 2, 3, 6, 11, 13, 26, 28, 34, 36, 46, 49, 53, 60, 64, 66, 79, 85, 86, 96, 111, 218, 222, 226, 265, 296, 297, 299
563Tadalafil1件: Tadalafil1件: D02008 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬7件: 6, 51, 75, 84, 86, 113, 210
564Tadalafil 20 mg film-coated tablets1件: Tadalafil1件: D02008 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
565Tadalafil 40 mg1件: Tadalafil1件: D02008 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
566Tadalafil and ambrisentan upfront combination therapy2件: Ambrisentan,
Tadalafil		2件: D02008 ,
D07077 		2件: EDNRA,
PDE5A 💬		9件: Calcium signaling pathway, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Purine metabolism, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬2件: 51, 86
567Tadalafil oral suspension1件: Tadalafil1件: D02008 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
568Tadalafil- Tablet or Oral suspension1件: Tadalafil1件: D02008 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
569TADALAFILO1件: Tadalafil1件: D02008 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
570Tamoxifen1件: Tamoxifen2件: D00966 ,
D08559 		2件: ESR1,
ESR2 💬		10件: Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬4件: 2, 86, 113, 227
571Tasigna1件: Nilotinib1件: D08953 4件: ABL1,
KIT,
PDGFRA,
PDGFRB 💬		33件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬2件: 34, 86
572Tasigna®1件: Nilotinib1件: D08953 4件: ABL1,
KIT,
PDGFRA,
PDGFRB 💬		33件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬1件: 86
573Tasigna® 150 mg1件: Nilotinib1件: D08953 4件: ABL1,
KIT,
PDGFRA,
PDGFRB 💬		33件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬1件: 86
574TBD----4件: 19, 86, 276, 299
575Tegaderm----1件: 86
576Terguride1件: Terguride1件: D01348 2件: DRD2,
PRL 💬		12件: Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway 💬2件: 51, 86
577Terguride 0,5mg tablet1件: Terguride1件: D01348 2件: DRD2,
PRL 💬		12件: Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 86
578Terguride 0.5 mg tablet1件: Terguride1件: D01348 2件: DRD2,
PRL 💬		12件: Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 86
579Tezosentan1件: Tezosentan---1件: 86
580The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:----1件: 86
581The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:----1件: 86
582Thelin1件: Sitaxentan1件: D07171 1件: EDNRA 💬7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
583Threonine1件: Threonine1件: D00041 --3件: 86, 96, 97
584Thrombin1件: Thrombin1件: D00090 --2件: 86, 88
585Tocilizumab1件: Tocilizumab1件: D02596 1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬21件: 2, 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331
586TPN171H----1件: 86
587TPN171H single dose----1件: 86
588Traclear----1件: 86
589Tracleer1件: Bosentan2件: D01227 ,
D07538 		2件: EDNRA,
EDNRB 💬		9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬8件: 13, 51, 84, 85, 86, 88, 210, 211
590TRACLEER 62,5 mg comprimidos recubiertos con película1件: Bosentan2件: D01227 ,
D07538 		2件: EDNRA,
EDNRB 💬		9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
591TRACLEER 62,5MG 56CPR RIV.1件: Bosentan2件: D01227 ,
D07538 		2件: EDNRA,
EDNRB 💬		9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
592TRACLEER*125MG 56CPR RIV.1件: Bosentan2件: D01227 ,
D07538 		2件: EDNRA,
EDNRB 💬		9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬2件: 51, 86
593TRACLEER*56CPR RIV 125MG1件: Bosentan2件: D01227 ,
D07538 		2件: EDNRA,
EDNRB 💬		9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬3件: 51, 86, 88
594Tracleer®----1件: 86
595Transdihydrolisuride----2件: 51, 86
596TRE----1件: 86
597Treprosinil Diethanolamine----1件: 86
598Treprostin----1件: 86
599Treprostinil1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬6件: 51, 84, 85, 86, 88, 210
600Treprostinil dietanolamina1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
601Treprostinil diethanolamine1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬2件: 51, 86
602Treprostinil Diolamine1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
603Treprostinil Inhalation Powder1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
604Treprostinil inhalations1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
605Treprostinil Injectable Product1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
606Treprostinil Palmitil1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
607TREPROSTINIL SODIUM1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬3件: 51, 86, 88
608Treprostinil Sodium Solution for Inhalation1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
609TREPROSTINIL SODIUM, UT-151件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
610Treprostinil, UT-15, LRX-15, 15AU81, BW A15AU, U-62, 8401件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
611Treprostinilo1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
612Trimetazidine1件: Trimetazidine1件: D08642 --3件: 2, 58, 86
613Trisuva(r)----1件: 86
614TRK-100STP----1件: 86
615Tyrosine1件: Tyrosine1件: D00022 --3件: 6, 86, 111
616Tyvaso1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
617Tyvaso Inhalation Solution1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
618Ubenimex1件: Ubenimex1件: D00087 1件: ANPEP 💬4件: Glutathione metabolism, Hematopoietic cell lineage, Metabolic pathways, Renin-angiotensin system 💬1件: 86
619Udenafil1件: Udenafil1件: D10027 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬2件: 86, 210
620UK 092480----1件: 86
621UK-92,480----1件: 86
622UK-92,480-10----1件: 86
623ULARITIDE1件: Ularitide---1件: 86
624Uptravi1件: Selexipag1件: D09994 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬3件: 84, 86, 88
625Urodilatin----1件: 86
626Usual Care----1件: 86
627UT-15C----1件: 86
628UT-15C (treprostinil diethanolamine)1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
629UT-15C 0.25 mg----1件: 86
630UT-15C 1 mg----1件: 86
631UT-15C 5 mg----1件: 86
632UT-15C LP----1件: 86
633UT-15C SR----2件: 51, 86
634UT-15C SR (treprostinil diethanolamine)1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
635UT-15C-SR----2件: 51, 86
636Vardenafil1件: Vardenafil3件: D02731 ,
D03260 ,
D08668 		1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬3件: 13, 86, 299
637Vasomera (PB1046) Injection----1件: 86
638Veletri1件: Epoprostenol2件: D00106 ,
D01337 		1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
639Ventavis1件: Iloprost1件: D02721 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
640Ventavis (Iloprost, BAYQ6256)1件: Iloprost1件: D02721 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
641Ventavis 101件: Iloprost1件: D02721 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
642Ventavis(Iloprost)1件: Iloprost1件: D02721 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
643VIAGRA1件: Sildenafil2件: D02229 ,
D08514 		1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬3件: 86, 96, 225
644VIP----3件: 49, 51, 86
645Volibris1件: Ambrisentan1件: D07077 1件: EDNRA 💬7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬4件: 51, 85, 86, 88
646VOLIBRIS 10 mg comprimidos recubiertos con película1件: Ambrisentan1件: D07077 1件: EDNRA 💬7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
647VOLIBRIS 5 mg comprimidos recubiertos con película1件: Ambrisentan1件: D07077 1件: EDNRA 💬7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
648VOLIBRIS® (ambrisentan)1件: Ambrisentan1件: D07077 1件: EDNRA 💬7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
649VOLIBRIS™ tablets1件: Ambrisentan1件: D07077 1件: EDNRA 💬7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
650Warfarin1件: Warfarin3件: D00564 ,
D01280 ,
D08682 		2件: NQO1,
VKORC1 💬		7件: Biosynthesis of cofactors, Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Metabolic pathways, Pathways in cancer, Ubiquinone and other terpenoid-quinone biosynthesis 💬13件: 6, 8, 13, 19, 46, 49, 66, 85, 86, 88, 91, 96, 97
651ZAMICASTAT1件: Zamicastat---1件: 86